JP2012524733A5 - - Google Patents

Download PDF

Info

Publication number
JP2012524733A5
JP2012524733A5 JP2012506340A JP2012506340A JP2012524733A5 JP 2012524733 A5 JP2012524733 A5 JP 2012524733A5 JP 2012506340 A JP2012506340 A JP 2012506340A JP 2012506340 A JP2012506340 A JP 2012506340A JP 2012524733 A5 JP2012524733 A5 JP 2012524733A5
Authority
JP
Japan
Prior art keywords
composition
vaccine
immunogenic
antigen
mycobacterium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012506340A
Other languages
English (en)
Japanese (ja)
Other versions
JP5839361B2 (ja
JP2012524733A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/DK2010/000054 external-priority patent/WO2010121618A1/en
Publication of JP2012524733A publication Critical patent/JP2012524733A/ja
Publication of JP2012524733A5 publication Critical patent/JP2012524733A5/ja
Application granted granted Critical
Publication of JP5839361B2 publication Critical patent/JP5839361B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012506340A 2009-04-24 2010-04-23 再活性化を予防する結核tbワクチン Expired - Fee Related JP5839361B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200900539 2009-04-24
DKPA200900539 2009-04-24
PCT/DK2010/000054 WO2010121618A1 (en) 2009-04-24 2010-04-23 A tuberculosis tb vaccine to prevent reactivation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015127000A Division JP6215260B2 (ja) 2009-04-24 2015-06-24 再活性化を予防する結核tbワクチン

Publications (3)

Publication Number Publication Date
JP2012524733A JP2012524733A (ja) 2012-10-18
JP2012524733A5 true JP2012524733A5 (enExample) 2013-06-06
JP5839361B2 JP5839361B2 (ja) 2016-01-06

Family

ID=43010694

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012506340A Expired - Fee Related JP5839361B2 (ja) 2009-04-24 2010-04-23 再活性化を予防する結核tbワクチン
JP2015127000A Active JP6215260B2 (ja) 2009-04-24 2015-06-24 再活性化を予防する結核tbワクチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015127000A Active JP6215260B2 (ja) 2009-04-24 2015-06-24 再活性化を予防する結核tbワクチン

Country Status (17)

Country Link
US (2) US9074001B2 (enExample)
EP (1) EP2421557B1 (enExample)
JP (2) JP5839361B2 (enExample)
KR (2) KR20120014176A (enExample)
CN (2) CN102413837B (enExample)
AU (1) AU2010238943B9 (enExample)
BR (1) BRPI1006452A2 (enExample)
CA (1) CA2759583C (enExample)
DK (1) DK2421557T3 (enExample)
ES (1) ES2714383T3 (enExample)
HK (1) HK1204549A1 (enExample)
IL (1) IL215591A (enExample)
MX (2) MX2011011186A (enExample)
PL (1) PL2421557T3 (enExample)
TR (1) TR201903223T4 (enExample)
WO (1) WO2010121618A1 (enExample)
ZA (1) ZA201108564B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2457926T3 (pl) 2005-04-29 2015-03-31 Glaxosmithkline Biologicals Sa Nowy sposób profilaktyki lub leczenia zakażenia m. tuberculosis
GB0618127D0 (en) * 2006-09-14 2006-10-25 Isis Innovation Biomarker
UA107330C2 (uk) * 2008-07-25 2014-12-25 Глаксосмітклайн Байолоджікалз С.А. Туберкульозний білок rv3616c та його застосування
WO2010010179A1 (en) 2008-07-25 2010-01-28 Glaxosmithkline Biologicals S.A. The tuberculosis rv2386c protein, compositions and uses thereof
EP2315597B1 (en) 2008-07-25 2017-08-23 GlaxoSmithKline Biologicals S.A. Novel compositions and methods
GB0906215D0 (en) 2009-04-09 2009-05-20 Lalvani Ajit Diagnostic test
PL2528621T3 (pl) 2010-01-27 2017-07-31 Glaxosmithkline Biologicals S.A. Zmodyfikowane antygeny gruźlicy
PL2661253T3 (pl) 2011-01-04 2017-08-31 Archivel Farma, Sl Preparat liposomowy odpowiedni do leczenia lub zapobiegania gruźlicy
ES2670493T3 (es) 2012-01-12 2018-05-30 Archivel Farma, S.L. Vacuna de MTB-C contra respuestas alérgicas
CN104736555B (zh) * 2012-10-23 2019-06-21 国家血清研究所 结核分枝杆菌疫苗
AU2014232335C1 (en) 2013-03-15 2016-09-01 The Trustees Of The University Of Pennsylvania Synthetic immunogens for prophylaxis or treatment of tuberculosis
US10641770B2 (en) * 2013-12-16 2020-05-05 Statens Serum Institut Diagnostic reagents for improved in vivo or in vitro cell-mediated immunological diagnosis of tuberculosis
RU2695462C2 (ru) * 2014-01-09 2019-07-23 Трансген Са Гибридизация гетероолигомерных микобактериальных антигенов
JP2017513860A (ja) * 2014-04-24 2017-06-01 スタテンス セールム インスティトゥート 新規結核菌(m.tuberculosis)ワクチン
CN104151433A (zh) * 2014-08-11 2014-11-19 兰州大学 一种结核分枝杆菌融合蛋白及其制备方法和应用
CN104225591A (zh) * 2014-09-15 2014-12-24 兰州大学 一种免疫佐剂及含有该免疫佐剂的疫苗
US20200148729A1 (en) * 2016-05-21 2020-05-14 Infectious Disease Research Institute Compositions and Methods for Treating Secondary Tuberculosis and Nontuberculosis Mycobacterium Infections
MX2020011298A (es) 2018-04-26 2021-01-29 Childrens Nat Medical Ct Composiciones de antígeno micobacteriano y métodos de uso.
CN110423279B (zh) * 2019-06-20 2021-07-27 扩增生物科技(北京)有限公司 结核分枝杆菌重组融合蛋白eecc及其制备方法和应用
CN115598041B (zh) * 2021-07-07 2025-08-19 中国科学院微生物研究所 结核鉴别诊断细胞因子及其在结核感染风险评估中的应用
KR102577332B1 (ko) * 2021-12-29 2023-09-11 재단법인 오송첨단의료산업진흥재단 항원성 및 안정성이 개선된 항원을 포함하는 잠복결핵 진단용 조성물
KR20250082868A (ko) 2023-11-30 2025-06-09 서울대학교산학협력단 분비형 코리스메이트 뮤테이즈 (Rv1885c)가 약화된 Mycobacterium bovis BCG 균주, 이를 포함하는 백신용 조성물 및 이의 용도
CN117777259B (zh) * 2024-02-23 2024-06-07 上海科新生物技术股份有限公司 检测结核感染的抗原组合物、试剂盒及其应用
CN120192426B (zh) * 2025-03-04 2025-11-11 江西澄实生物科技有限公司 一种预防沙门氏菌感染的疫苗及其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599230A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4599231A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4608251A (en) 1984-11-09 1986-08-26 Pitman-Moore, Inc. LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues
US4601903A (en) 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
US6641814B1 (en) * 1997-04-02 2003-11-04 Statens Serum Institut Nucleic acids fragments and polypeptide fragments derived from M. tuberculosis
US5955077A (en) * 1993-07-02 1999-09-21 Statens Seruminstitut Tuberculosis vaccine
CN1105236A (zh) * 1993-11-13 1995-07-19 丛繁滋 肺结核防传播及治疗用气雾剂及其制备方法
CN1051234C (zh) * 1994-04-15 2000-04-12 焦安国 一种治疗结核病的药物
ATE339436T1 (de) 1995-06-07 2006-10-15 Sanofi Pasteur Inc Expression von lipoproteinen
US6338852B1 (en) * 1995-09-01 2002-01-15 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6982085B2 (en) * 1997-04-02 2006-01-03 Statens Serum Institut TB diagnostic based on antigens from M. tuberculosis
EP1200466A2 (en) 1999-07-13 2002-05-02 Statens Serum Institut Tuberculosis vaccine and diagnostics based on the mycobacterium tuberculosisesat-6 gene family
WO2001079274A2 (en) 2000-04-19 2001-10-25 Statens Serum Institut Tuberculosis antigens and methods of use thereof
GB0030368D0 (en) 2000-12-13 2001-01-24 Inst Of Molecul & Cell Biology Dormancy-induced mycobacterium proteins
CA2433236C (en) * 2001-01-08 2016-10-04 Isis Innovation Limited Assay to determine efficacy of treatment for m. tuberculosis infection
DE60236573D1 (de) * 2002-04-05 2010-07-15 Pasteur Institut Identifizierung der Virulenz-assoziierten Regionen RD1 und RD5, die die Entwicklung von verbesserten Impfstoffen mit M. bovis BCG und M. microti ermöglicht
EP1523331B1 (en) * 2002-07-13 2013-02-27 Statens Serum Institut Therapeutic tb vaccine
WO2004067718A2 (en) 2003-01-24 2004-08-12 Emory University Necrosis-deficient mutants of tuberculosis bacteria
EP2226332A1 (en) * 2004-06-17 2010-09-08 Beckman Coulter, Inc. Mycobacterium tuberculosis epitopes and methods of use thereof
NZ555907A (en) * 2004-11-16 2009-12-24 Aeras Global Tb Vaccine Found Multivalent vaccines comprising recombinant viral vectors
MX2007008182A (es) * 2005-01-05 2008-02-19 Isis Innovation Composiciones para inmunizar contra micobacteria.
PL2457926T3 (pl) 2005-04-29 2015-03-31 Glaxosmithkline Biologicals Sa Nowy sposób profilaktyki lub leczenia zakażenia m. tuberculosis
AU2006261445B2 (en) 2005-06-23 2011-03-31 Statens Serum Institut Tuberculosis vaccines comprising antigens expressed during the latent infection phase
RU2490024C2 (ru) * 2006-06-28 2013-08-20 Статенс Серум Инститьют Расширение спектра т клеток для включения субдоминантных эпитопов путем вакцинации с антигенами, доставленными как белковые фрагменты или пептидные коктейли
UA107330C2 (uk) 2008-07-25 2014-12-25 Глаксосмітклайн Байолоджікалз С.А. Туберкульозний білок rv3616c та його застосування

Similar Documents

Publication Publication Date Title
JP2012524733A5 (enExample)
TWI638829B (zh) 分枝桿菌抗原疫苗
CN102413837B (zh) 预防再激活的结核病tb疫苗
US10004793B2 (en) M.tuberculosis vaccines
JP2015536309A (ja) 結核菌(m.tuberculosis)ワクチン
CN110506108B (zh) 过表达phoP-phoR的重组BCG
WO2016201825A1 (zh) 结核分枝杆菌抗原及其应用
CN102180974B (zh) 一种结核杆菌融合蛋白及其制备方法和应用
JP2016513078A (ja) 一段階または多段階のトリ型結核菌亜種副結核症サブユニット・ワクチン
CN101451145A (zh) 基于t细胞表位的结核基因疫苗及其制备方法和应用
Li et al. Advancements in the development of nucleic acid vaccines for syphilis prevention and control
Lu et al. Immunogenicity and protective efficacy against murine tuberculosis of a prime‐boost regimen with BCG and a DNA vaccine expressing ESAT‐6 and Ag85A fusion protein
JP2015513314A5 (enExample)
Wang et al. Immunogenicity and protective efficacy of a novel recombinant BCG strain overexpressing antigens Ag85A and Ag85B
CN101455846A (zh) 脱乙酰壳聚糖递送系统组装的结核基因疫苗及其制备和应用
CN108330142A (zh) 一种具有免疫保护作用的美人鱼发光杆菌溶血素Hlych蛋白
Deng et al. Improved Immunogenicity of Recombinant Mycobacterium bovis Bacillus Calmette‐Guérin Strains Expressing Fusion Protein Ag85A‐ESAT‐6 of Mycobacterium tuberculosis
US10406219B2 (en) Multivalent Brucella vaccine for protection against mycobacterial infections and methods of using the same
EP2757155B1 (en) Recombinant bcg vaccine
CN102772795B (zh) 布鲁氏菌鞭毛蛋白bmeii1112在制备布鲁氏菌亚单位疫苗中的应用
CN104371013B (zh) 牛分枝杆菌cfp-10的迟发型变态反应抗原表位多肽及其应用
US9562080B2 (en) Lyme disease vaccine, genetic construct, recombinant protein, method for designing genetic construct, method for producing vaccine, method for producing recombinant proteins, use of recombinant proteins in the production of lyme disease vaccine
RU2776479C1 (ru) Живая пробиотическая вакцина, содержащая консервативные эпитопы вируса гриппа А (LAH+4M2e), для профилактики гриппозной инфекции
CN111948387A (zh) 结核分枝杆菌抗原蛋白Rv1485在制备结核疫苗中的应用
JP2011102299A5 (enExample)